Date: 2017-07-05
Type of
information: Treatment of the first patient
phase: 1
Announcement: initiation of the trial
Company: BeiGene (China)
Product: BGB-3111
Action
mechanism:
- kinase inhibitor/Bruton tyrosine kinase inhibitor. BGB-3111 is an investigational, oral, highly selective and potent inhibitor of Bruton tyrosine kinase (BTK). Bruton tyrosine kinase (BTK), a member of the TEC family of kinases, is a signaling molecule positioned within the B-cell receptor signaling cascade. BTK is predominantly expressed in B lymphocytes at various stages of development. Activation of BTK in B cells initiates a series of signaling events that leads to subsequent NF-?B activation and the expression of genes involved in proliferation and survival. Several BTK inhibitors have demonstrated sustained antitumor responses as a single agent in patients with B-cell malignancies.
Disease: B-cell malignancies
Therapeutic
area: Cancer - Oncology
Country: China
Trial
details:
- The Phase I multi-center, open label clinical trial of BGB-3111 is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of this agent in Chinese patients with B-cell malignancies, and to determine the recommended Phase II dose in Chinese patients. Professor Jun Zhu, MD, a medical oncologist at the Beijing Cancer Hospital will be the leading principal investigator of the study.
Latest
news:
- • On July 5, 2016, BeiGene announced the dosing of the first patient in China in a Phase I clinical trial of BGB-3111 for the treatment of various B-cell malignancies. Another phase I study is ongoing in Australia, New Zealand, South Korea and the United States.
Is
general: Yes
